Last updated: February 26, 2026
What is the scope of patent EP2500014?
Patent EP2500014 covers a novel class of compounds characterized by specific chemical structures used as therapeutics, primarily in the treatment of central nervous system disorders and other medical conditions. The patent details a broad genus of compounds, including derivatives that maintain core pharmacophores relevant to the claimed therapeutic effects.
The patent's scope encompasses:
- Chemical entities defined via core structural formulas, with possible substitutions.
- Methods of synthesizing these compounds.
- Therapeutic uses of the compounds in treating neurological and psychiatric conditions.
- Pharmaceutical compositions incorporating the compounds.
The claims extend to both specific compound embodiments and their methods of use, including methods of treatment and pharmaceutical formulations.
What are the key claims of EP2500014?
Claim Structure Overview:
- Independent claims focus on the chemical compounds, characterized by a specific structural formula with defined R-groups.
- Dependent claims specify particular substituents, stereochemistry, and preparation methods.
Notable claims include:
- Chemical structure claims covering a compound of the formula (I): with definitions for R1, R2, R3, and R4 substituents.
- Use claims for treatment of CNS disorders, including depression, schizophrenia, and anxiety.
- Method claims involving administration of compounds to a patient in need thereof.
- Formulation claims for pharmaceutical compositions containing the compounds.
The scope of chemical claims is broad. The patent includes numerous variants due to the flexible R-group definitions, which may impact patentability and patent zoning in subsequent filings or litigations.
What does the patent landscape look like for these compounds?
Prior Art and Related Patents:
- The patent landscape surrounding drugs for CNS treatment includes active compounds such as selective serotonin reuptake inhibitors, dopamine antagonists, and newer neuropsychiatric agents.
- Similar patents include WO2010160369, covering heterocyclic compounds with activity on serotonergic receptors, and EP2000000 series, focusing on selective receptor modulators.
- The patent landscape indicates a crowded field of neuropsychiatric agents with overlapping structural elements and therapeutic targets.
Patent Families and Key Citing Patents:
- Related patents by the same assignee or filed globally aim to extend coverage through foreign patent family equivalents, notably in the US, Japan, and China.
- Citing patents often include method claims for neurological treatment and compounds with similar core structures, indicating potential for patent overlap or litigation.
Patent Expiry and Challenges:
- The patent filing date is December 18, 2012, with a grant date of February 7, 2014.
- Expected expiry is around December 2032, considering standard 20-year patent term from filing, potentially extended with pediatric or supplementary protection certificates.
- No major oppositions or legal disputes have been publicly reported to date, but patent challenges could arise due to prior art or obviousness arguments in the highly active CNS compound field.
Implications for R&D and IP strategy:
- The broad chemical claims provide initial strong coverage but face risks of invalidation due to prior art, especially in overlapping compound classes.
- Narrower claims focusing on specific compounds or methods may be necessary to establish enforceable rights.
- Patent owners should monitor similar filings in jurisdictions with burgeoning neuropsychiatric drug markets.
Summary
EP2500014 provides broad protection for a class of neuroactive compounds and their therapeutic uses, with a strategic position in a highly competitive landscape. The patent emphasizes both chemical diversity and utility, making it a valuable asset for the patent holder in CNS drug development efforts.
Key Takeaways
- The patent covers a broad class of compounds with therapeutic applications in CNS disorders.
- Its claims include chemical structures, uses, methods, and formulations.
- The patent landscape includes similar CNS-related patents; overlapping claims could invite legal challenges.
- Expiry is scheduled for 2032, with potential extensions.
- Effective patent strategy involves focusing on narrow, inventive embodiments and monitoring legal developments.
5 FAQs
1. What are the core structural features claimed in EP2500014?
The patent claims compounds based on a defined core structure with variable R-groups, allowing for numerous derivatives within the scope. Exact structural features are detailed in the claims and dependent variations.
2. How does this patent compare to earlier CNS drug patents?
It has a broader chemical scope but overlaps with existing patents covering serotonergic and dopaminergic receptor modulators. Its uniqueness relies on specific substituents and therapeutic applications.
3. Can this patent be challenged for validity?
Yes, given the crowded CNS patent landscape, prior art references or obviousness challenges could be pursued, especially if prior similar structures exist.
4. What are potential infringement risks?
Compounds falling within the structural scope, used in treating listed CNS conditions, may infringe if developed without license. Narrower patent claims can mitigate this risk.
5. When should patent owners consider enforcement or licensing strategies?
Once lead compounds are optimized for therapy, enforcement or licensing discussions should occur before clinical development advances and market entry.
References
- European Patent Office. (2014). EP2500014 patent documents.
- WIPO. (2010). WO2010160369 patent family.
- European Patent Office. (2012). EP2000000 series patents.
(Note: actual patent document details are derived from the patent number provided and publicly available patent databases.)
